Position in NCEL
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$1,450
+$1,450 QoQ
Shares Held
684
+1700.0% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NCEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026UBS Group AG holds $8,789,681,375 across 562 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
5,450,825 | $1,020,369,609 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
17,466,641 | $618,144,423 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
3,399,221 | $416,676,508 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
712,259 | $353,800,411 | |
| 5 | MRNA |
Moderna, Inc.
|
4,463,211 | $312,558,664 | |
| 6 | INSM |
INSMED Inc
|
2,584,446 | $275,553,630 | |
| 7 | ABVX |
Abivax S.A.
|
1,844,918 | $245,853,771 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
401,708 | $215,697,109 |
All Filings in NCEL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,450 | 684 | Shares | Defined | 2026-05-05 | |
| 2025-09-30 NLSP | — | 38 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 NLSP | — | 14,982 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 NLSP | — | 25,737 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 NLSP | — | 8,292 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 NLSP | — | 4,719 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||